Sarepta Therapeutics (SRPT +8%) moves up on the back of on a positive article in Seeking Alpha...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT +8%) moves up on the back of on a positive article in Seeking Alpha today, saying the stock looks "ridiculously overvalued" at current levels. Contributor Sean Anderson notes a number of potential catalysts to move the stock higher, but most significant is how little attention the stock currently gets on the Street, which could quickly change if of it's eteplirsen, a potential blockbuster treatment for Duchenne's disease, to receive early approval.